Literature DB >> 22156218

2011 update of the drug resistance mutations in HIV-1.

Victoria A Johnson1, Vincent Calvez, Huldrych F Günthard, Roger Paredes, Deenan Pillay, Robert Shafer, Annemarie M Wensing, Douglas D Richman.   

Abstract

This November 2011 edition of the IAS-USA drug resistance mutations list updates the figures last published in December 2010 (Johnson VA et al, Top HIV Med, 2010;18:156-163).

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22156218      PMCID： PMC6148877     

Source DB:  PubMed          Journal:  Top Antivir Med        ISSN： 2161-5853


  58 in total

1.  Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.

Authors:  Jeannette M Whitcomb; Neil T Parkin; Colombe Chappey; Nicholas S Hellmann; Christos J Petropoulos
Journal:  J Infect Dis       Date:  2003-09-16       Impact factor: 5.226

2.  Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy.

Authors:  Michela Violin; Alessandro Cozzi-Lepri; Rossella Velleca; Antonella Vincenti; Salvatore D'Elia; Francesco Chiodo; Florio Ghinelli; Ada Bertoli; Antonella d'Arminio Monforte; Carlo Federico Perno; Mauro Moroni; Claudia Balotta
Journal:  AIDS       Date:  2004-01-23       Impact factor: 4.177

3.  Prevalence, mutation patterns, and effects on protease inhibitor susceptibility of the L76V mutation in HIV-1 protease.

Authors:  Thomas P Young; Neil T Parkin; Eric Stawiski; Tami Pilot-Matias; Roger Trinh; Dale J Kempf; Michael Norton
Journal:  Antimicrob Agents Chemother       Date:  2010-08-30       Impact factor: 5.191

Review 4.  Update of the drug resistance mutations in HIV-1: 2007.

Authors:  Victoria A Johnson; Françoise Brun-Vézinet; Bonaventura Clotet; Huldrych F Günthard; Daniel R Kuritzkes; Deenan Pillay; Jonathan M Schapiro; Douglas D Richman
Journal:  Top HIV Med       Date:  2007 Aug-Sep

5.  Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial.

Authors:  Vincent Calvez; Dominique Costagliola; Diane Descamps; Anne Yvon; Gilles Collin; Agnès Cécile; Constance Delaugerre; Florence Damond; Anne-Geneviève Marcelin; Sophie Matheron; Anne Simon; Marc-Antoine Valantin; Christine Katlama; Françoise Brun-Vézinet
Journal:  Antivir Ther       Date:  2002-09

6.  Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.

Authors:  Calvin J Cohen; Jaime Andrade-Villanueva; Bonaventura Clotet; Jan Fourie; Margaret A Johnson; Kiat Ruxrungtham; Hao Wu; Carmen Zorrilla; Herta Crauwels; Laurence T Rimsky; Simon Vanveggel; Katia Boven
Journal:  Lancet       Date:  2011-07-16       Impact factor: 79.321

7.  The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis.

Authors:  Richard H Haubrich; Carol A Kemper; Nicholas S Hellmann; Philip H Keiser; Mallory D Witt; Donald N Forthal; John Leedom; Matthew Leibowitz; Jeannette M Whitcomb; Douglas Richman; J Allen McCutchan
Journal:  AIDS       Date:  2002-10-18       Impact factor: 4.177

8.  Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.

Authors:  Michael D Miller; Nicolas Margot; Biao Lu; Lijie Zhong; Shan-Shan Chen; Andrew Cheng; Michael Wulfsohn
Journal:  J Infect Dis       Date:  2004-02-10       Impact factor: 5.226

9.  Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience.

Authors:  Lisa M Demeter; Victor DeGruttola; Stephanie Lustgarten; Daniel Bettendorf; Margaret Fischl; Susan Eshleman; William Spreen; Bach-Yen Nguyen; Christine E Koval; Joseph J Eron; Scott Hammer; Kathleen Squires
Journal:  HIV Clin Trials       Date:  2008 Jan-Feb

10.  Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.

Authors:  Viktor von Wyl; Sabine Yerly; Jürg Böni; Philippe Bürgisser; Thomas Klimkait; Manuel Battegay; Enos Bernasconi; Matthias Cavassini; Hansjakob Furrer; Bernard Hirschel; Pietro L Vernazza; Martin Rickenbach; Bruno Ledergerber; Huldrych F Günthard
Journal:  Clin Infect Dis       Date:  2008-04-15       Impact factor: 9.079
View more
  142 in total

1.  No increase of drug-resistant HIV type 1 prevalence among drug-naive individuals in Northern Vietnam.

Authors:  Vuong Thi Tran; Azumi Ishizaki; Cuong Hung Nguyen; Huyen Thi Thanh Hoang; Hung Viet Pham; Xiuqiong Bi; Thuc Van Pham; Hiroshi Ichimura
Journal:  AIDS Res Hum Retroviruses       Date:  2012-03-06       Impact factor: 2.205

2.  Antiretroviral drug susceptibility among HIV-infected adults failing antiretroviral therapy in Rakai, Uganda.

Authors:  Steven J Reynolds; Oliver Laeyendecker; Gertrude Nakigozi; Joel E Gallant; Wei Huang; Sarah E Hudelson; Thomas C Quinn; Kevin Newell; David Serwadda; Ronald H Gray; Maria J Wawer; Susan H Eshleman
Journal:  AIDS Res Hum Retroviruses       Date:  2012-04-26       Impact factor: 2.205

3.  Antiviral drug resistance and the need for development of new HIV-1 reverse transcriptase inhibitors.

Authors:  Eugene L Asahchop; Mark A Wainberg; Richard D Sloan; Cécile L Tremblay
Journal:  Antimicrob Agents Chemother       Date:  2012-06-25       Impact factor: 5.191

4.  Pulsed EPR characterization of HIV-1 protease conformational sampling and inhibitor-induced population shifts.

Authors:  Zhanglong Liu; Thomas M Casey; Mandy E Blackburn; Xi Huang; Linh Pham; Ian Mitchelle S de Vera; Jeffrey D Carter; Jamie L Kear-Scott; Angelo M Veloro; Luis Galiano; Gail E Fanucci
Journal:  Phys Chem Chem Phys       Date:  2016-02-17       Impact factor: 3.676

5.  Molecular mechanisms of HIV type 1 prophylaxis failure revealed by single-genome sequencing.

Authors:  Hui Li; Lily Blair; Yalu Chen; Gerald Learn; Katja Pfafferott; Mina John; Tanmoy Bhattacharya; Beatrice H Hahn; Simon Mallal; George M Shaw; Katharine J Bar
Journal:  J Infect Dis       Date:  2013-09-09       Impact factor: 5.226

6.  Identifying recombination hot spots in the HIV-1 genome.

Authors:  Redmond P Smyth; Timothy E Schlub; Andrew J Grimm; Caryll Waugh; Paula Ellenberg; Abha Chopra; Simon Mallal; Deborah Cromer; Johnson Mak; Miles P Davenport
Journal:  J Virol       Date:  2013-12-26       Impact factor: 5.103

7.  Rapid deep sequencing of patient-derived HIV with ion semiconductor technology.

Authors:  Max W Chang; Glenn Oliveira; Jinyun Yuan; Jason F Okulicz; Samuel Levy; Bruce E Torbett
Journal:  J Virol Methods       Date:  2013-02-04       Impact factor: 2.014

8.  Antiretroviral treatment interruptions induced by the Kenyan postelection crisis are associated with virological failure.

Authors:  Marita Mann; Lameck Diero; Emmanuel Kemboi; Fidelis Mambo; Mary Rono; Wilfred Injera; Allison Delong; Leeann Schreier; Kara W Kaloustian; John Sidle; Nathan Buziba; Rami Kantor
Journal:  J Acquir Immune Defic Syndr       Date:  2013-10-01       Impact factor: 3.731

9.  Genetic Changes in HIV-1 Gag-Protease Associated with Protease Inhibitor-Based Therapy Failure in Pediatric Patients.

Authors:  Jennifer Giandhari; Adriaan E Basson; Ashraf Coovadia; Louise Kuhn; Elaine J Abrams; Renate Strehlau; Lynn Morris; Gillian M Hunt
Journal:  AIDS Res Hum Retroviruses       Date:  2015-06-04       Impact factor: 2.205

10.  Multicenter quality control of hepatitis C virus protease inhibitor resistance genotyping.

Authors:  Sophie Vallet; Sylvie Larrat; Syria Laperche; Hélène Le Guillou-Guillemette; Florence Legrand-Abravanel; Françoise Bouchardeau; Adeline Pivert; Cécile Henquell; Audrey Mirand; Elisabeth André-Garnier; Valérie Giordanengo; Gisèle Lagathu; Vincent Thibault; Caroline Scholtes; Evelyne Schvoerer; Catherine Gaudy-Graffin; Sarah Maylin; Pascale Trimoulet; Etienne Brochot; Sébastien Hantz; Joël Gozlan; Anne-Marie Roque-Afonso; Patrick Soussan; Jean-Christophe Plantier; Charlotte Charpentier; Stéphane Chevaliez; Philippe Colson; Vincent Mackiewicz; Lina Aguilera; Sylvain Rosec; Stéphanie Gouriou; Nelly Magnat; Françoise Lunel-Fabiani; Jacques Izopet; Patrice Morand; Christopher Payan; Jean-Michel Pawlotsky
Journal:  J Clin Microbiol       Date:  2013-02-20       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.